Investigational Drug Information for Palovarotene
✉ Email this page to a colleague
What is the drug development status for Palovarotene?
Palovarotene is an investigational drug.
There have been 10 clinical trials for Palovarotene.
The most recent clinical trial was a Phase 2 trial, which was initiated on November 28th 2017.
The most common disease conditions in clinical trials are Myositis Ossificans, Osteophyte, and Osteochondromatosis. The leading clinical trial sponsors are Clementia Pharmaceuticals Inc., Ipsen, and [disabled in preview].
There are fifteen US patents protecting this investigational drug and one hundred and eighty-five international patents.
Summary for Palovarotene
| US Patents | 15 |
| International Patents | 185 |
| US Patent Applications | 58 |
| WIPO Patent Applications | 35 |
| Japanese Patent Applications | 11 |
| Clinical Trial Progress | Phase 2 (2017-11-28) |
| Vendors | 47 |
Recent Clinical Trials for Palovarotene
| Title | Sponsor | Phase |
|---|---|---|
| A Rollover Study to Further Evaluate the Safety and Efficacy of Palovarotene Capsules in Male and Female Participants Aged ≥14 Years With Fibrodysplasia Ossificans Progressiva (FOP) Who Have Completed the Relevant Parent Studies. | Ipsen | Phase 3 |
| Study Evaluating the Effect of Food on the Pharmacokinetics of Palovarotene and the Effect of Palovarotene on the Pharmacokinetics of the CYP3A4 Substrate Midazolam in Two Cohorts of Healthy Adult Subjects | Clementia Pharmaceuticals Inc. | Phase 1 |
| Study to Assess Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Doses of Palovarotene Ophthalmic Solution in Healthy Adult Subjects | Ipsen | Phase 1 |
Clinical Trial Summary for Palovarotene
Top disease conditions for Palovarotene
Top clinical trial sponsors for Palovarotene
US Patents for Palovarotene
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| Palovarotene | ⤷ Try a Trial | Therapeutic agent for keratoconjunctive disorders | YAMAGUCHI UNIVERSITY (Yamaguchi, JP) | ⤷ Try a Trial |
| Palovarotene | ⤷ Try a Trial | Controlled release dosage form | TRIASTEK, INC. (Nanjing, CN) | ⤷ Try a Trial |
| Palovarotene | ⤷ Try a Trial | Inhibitors of activin receptor-like kinase | BLUEPRINT MEDICINES CORPORATION (Cambridge, MA) | ⤷ Try a Trial |
| Palovarotene | ⤷ Try a Trial | Composition and method for muscle repair and regeneration | Thomas Jefferson University (Philadelphia, PA) | ⤷ Try a Trial |
| Palovarotene | ⤷ Try a Trial | Small molecule agonists and antagonists of NR2F6 activity in animals | Zander Therapeutics, Inc. (La Mesa, CA) | ⤷ Try a Trial |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for Palovarotene
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| Palovarotene | Australia | AU2013342882 | 2032-11-08 | ⤷ Try a Trial |
| Palovarotene | Australia | AU2018217197 | 2032-11-08 | ⤷ Try a Trial |
| Palovarotene | Brazil | BR112015010428 | 2032-11-08 | ⤷ Try a Trial |
| Palovarotene | Canada | CA2890424 | 2032-11-08 | ⤷ Try a Trial |
| Palovarotene | Chile | CL2015001225 | 2032-11-08 | ⤷ Try a Trial |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
